Summary: The aim of this study was to determine the prevalence of venous thromboembolism (VT) in current prophylactic practice with low-molecular-weight heparin (LMWH) among medical inpatients and to analyze associated risk factors for VT.
A cross-sectional survey on five given days was conducted in the medical departments of a university hospital. The prevalence of prophylaxis and confirmed VT was measured. Risk markers for receiving high doses of LMWH and for VT under prophylaxis were assessed by logistic regression models.
Of 1194 inpatients, 1 .4% suffered VT. The mean proportion of patients with LMWH prophylaxis was 24% (range: 4-64&deg;k). The prevalence of VT was higher among inpatients receiving prophylaxis than among those patients not receiving prophylaxis (3.5% vs. 0.7%, p = 0.002). Under prophylaxis, independent risk markers for thrombosis were history of vein thrombosis (odds ratio [OR]: 4.03; confidence interval [95%CI]: 1.04-15.62) and age (OR: 1.08 ; 95%CI: 1.01-1.15).
Two factors were independently associated with the prescription of high doses of LMWH: obesity was positively associated (OR: 7.50; 95%CI: 2.97-18.92; p < 0.0001) and respiratory insufficiency was negatively associated.
In medical departments, current prophylaxis practice leads to many patients being given LMWH. LMWH doses and other preventive measures should be adapted in high-risk inpatients.
The benefits of using heparin for prophylaxis of venous thromboembolism (VT) in surgical inpatients, including deep vein thrombosis and pulmonary embolism, have been clearly demonstrated. As a result, guidelines for prophylaxis of VT have been published (I). In contrast, few clinical studies have estimated the incidence of VT in medical populations. In autopsy studies of inpatients (2,3), the incidence of deep vein thrombosis has been estimated to be 23%, whereas the incidence of pulmonary embolism has been estimated to be 24°~~. Systematic leg scans of inpatients in placebo groups have been used in clinically controlled studies to screen for vein thrombosis, which was found to be prevalent (4-7).
Consequently, the recommendations established for surgical inpatients have been applied to medical inpatients in order to prevent VT (1); thus, low-molecularweight heparin (LMWH) is routinely used in clinical practice. According to these recommendations, doses of LMWH are usually adjusted to the risk of VT established for surgical patients (1, 8) . The efficacy of LMWH for preventing VT in medical patients has recently been con t firmed (9) . ! The frequency of VT associated with current care practice has never been evaluated in an unselected cohort ! E of medical inpatients (10) . Therefore, we conducted a I ' survey in a university public hospital: 1) to evaluate the / ' frequency of thromboembolic events in hospitalized patients treated according to current preventive practice, 2) to analyze the risk factors for VT events in this popula-i tion, and 3) to describe the use of LMWH for prophy-/ laxis in medical units.
j PATIENTS AND METHODS

) Study design
A cross-sectional survey using structured questionnaires was conducted between February and June 1 ~~7 ! < in a university hospital in Paris, France. The survey was / performed on 5 given days. Data were collected from physicians responsible for inpatients. To be sure only I new patients were investigated at each evaluation, the period between days of investigation was longer than l5 days in all cases; the mean hospital stay in the medical departments was less than 10 days. Patients under prophylaxis still hospitalized at a subsequent evaluation were included only once.
Patients
All patients hospitalized in departments of specialized medicine (internal medicine, rheumatology, pneumology, endocrinology, and gastroenterology) in a l02'7-hed university hospital (of which 51'~ beds are in medical services) were included. Patients in day and week care units, intensive care units, and departments of psychiatry and cardiology were excluded. Patients receiving curative doses of anticoagulants and patients hospitalized with the diagnosis of VT were also excluded from the study.
Questionnaires
Data were collectcd using three structured questionnaires. The first questionnaire asked for the numbers of inpatients on the given day, inpatients treated with curative or prophylactic doses of LMWH, and inpatients that presented with VT during the current hc~~pitatiz~itic~t~:
The second questionnaire asked for information about patients receiving anticoagulant prophylaxis for VT. The data collected included demographic characteristics (sex, age), clinical characteristics (weight, height, diagnosis, and comorbidity leading to the hospitalization), risk factors for VT, and type of prophylaxis (LMWH, antivitamin K, compression stockings). The risk factors investigated were selected from those identified by previous studies (2-5,l 11-14) . They included history of VT, canc~r or myeloproliferative disorder, thrombophilia, cardiac or respiratory insufficiency, coronary insufficiency, venous insufficiency, obesity, arteritis, sepsis, digestive or rheumatic inflammatory disease, stroke, oestrogen therapy, paralysis of the lower limbs, and recent surgery. Adverse effects of prophylaxis with heparin were also recorded.
A third questionnaire collected data on inpatients that presented with VT during the current hospitalization. This questionnaire asked for the same data as the second and for further information about the type of VT (deep vein thrombosis or pulmonary embolism) and the lag between admission and VT.
Venous thrombotic events
The physician defined VT on clinical grounds, and ' thus only clinical events were considered. To be recorded as VT, the clinical diagnosis had to be confirmed by phlebography for proximal or distal deep vein thrombosis or by echca-dc~~pler for proximal deep vein thrombosis and by isotopic lung scan (in cases of high probability risk) or pulmonary angiography for pulmonary embolism. Only VT diagnosed during hospitalization was con-sidered. All cases of VT diagnosed on admission or durthe first 24 hours of hospitalization were excluded.
Variable definitions
Risk factors for VT were defined according to previous studies (2-~5,i I-i~:): History of VT included previous confirmed deep venous thrombosis or pulmonary embolism. Cancer, myeloproliferative disorders, and digestive and rheumatic inflammatory diseases were only considered if the disease was progressing. Thrombophilia was recorded in cases of deficiency in coagulation protein, activated protein C resistance, antiphospholipid syndromes, or polycythemia. Only acute cardiac or respiratory insufficiencies were considered. Obesity was defined by a body mass index (BMI) greater than 30. Recent surgery was noted if pelvic, abdominal, thoracic, ' or lower limb surgery had been performed within two months. Only strokes within the preceeding 2 months were recorded. Venous insufficiency included varicose veins and postphlebitic syndromes.
Inpatients were classified according to the level of risk for VT, adapted from previous recommendations for suric:al patients. This classification defines categories of risk for VT, as described by Saltzman et at. (15) , as low (I), moderate (II), or high (111). The autonomy of each patient was analyzed and classified as bedridden (1), able to stay on a chair (11), or able to walk unaided (111).
As described in the recommendations for surgical patients, prophylaxis with LMWH was defined as low preventive dose (0.2 ml [20mg]/day enoxaparin) or high preventive dose (0.4 ml [40 mg]/day enoxaparin) (1, 8) .
Statistical analysis
Data were analyzed as appropriate using standard descriptive statistics of mean, standard deviation (SD), and frequency. Analyses of variance, chi-square tests, and Fisher's exact test were used as appropriate to compare the characteristics of inpatients with and without VT and the characteristics of inpatients receiving and not receiving prophylaxis. Statistical significance was set at p < 0.05. Data were further explored using conditional logistic regression models. Patient characteristics found to be different with a p value < 25% were included in the initial models. Age was considered as a continuous variable. Backward stepwise procedures were used to include those factors giving a significant explanation of outcomes in the final models only. Associations are expressed using odds ratios (OR) and their 95% confidence intervals (CI). The SPSS software package (SPSS@ for Windows@, version 6.1.2, Copyright SPSS Inc., 1989-1995) was used for statistical analyses.
RESULTS
Description of the population studied A total of 1194 patients were hospitalized on the 5 given days. Numbers of patients did not differ between the days investigated. The distribution of patients among the medical departments is shown in Table l.
Prevalence of venous thromboembolism
Of these l 194 inpatients, 17 (1.4%; 95% Cl: 0.8-2. 1 %) had deep vein thrombosis during hospitalization, and two also had associated pulmonary embolism. VT was diagnosed in mean on the fifth day (range: 2-'10) of hospitalization. The prevalence of VT did not differ between the medical departments (Table 1) .
Patients receiving prophylaxis
Two hundred eighty-seven inpatients (24%) received LMWH prophylaxis for VT. Only l ~'~; of inpatients also wore compression stockings. The mean age of patients receiving prophylaxis was 60 years (SD: 5), and 63% of the patients were women. The proportion of patients receiving prophylaxis was different in the medical departments with different specialities, ranging from 4% in thẽ ncic~crinc~lc>~y department to 64% in the pneumotogy department (Table t ~: Underlying diseases are shown in Table 2 . Patients were considered to be at low risk for VT (risk 1) in 109 cases (38'%), at moderate risk (risk 11) in 160 cases (56%), and at high risk (risk !!!) in ~~ cases (6%). Patients were bedridden in 24% of the cases, able ' to stay on a chair in 33%% of the cases, and ~~61~ to walk in 43% of the cases. Two adverse effects of prophylaxis with LMWH, one case of hematoma and one case ofthrombopenia (I):'7~I~); were noted.
Low-dose LMWH prophylaxis was given to ~~~%x of treated inpatients and high doses were given to 1 2C% of treated inpatients. Factors associated with the dose of LMWH included obesity (BMI > 30), history of VT, venous insufficiency, and respiratory insufficiency (Table 3 ). However, two independent factors, were associated with the prescription of high doses of LMWH: 'I~11~I ~ 30 (OR: 7.5(J; 95% C!: '~.~7--18.92; p < .(I~t~l) was positively associated and respiratory insufficiency (OR: 0. 19; 95% C!: 0.02-L49; ~ = 0. I ?) was negatively associated. Risk factors for venous thromboembolism among patients. on prophylaxis The prevalence of VT among inpatiehts receiving prophylaxis (3.3%: 10/287) was greater (p = (~.(~t)'~) than the prevalence among inpatients without prophylaxis, (0.7%; 7/lL)07). inpatients on prophylaxis who suffered VT were older, more frequency reported a history of ~lT, and less autonomous than the inpatients receiving pro-Iahylttxi.~; without VT (Table 4 ). 
DISCUSSION
Using a cross-sectional survey in a university hospital, based on a series of given days, we found a VT prevalence of 1.4% in medical inpatients. This study also showed that approximately one quarter of medical inpatients received VT preventive treatment with LMWH and describes the LMWH doses used. We are aware of no similar study including the inpatients of each department in a university hospital. For medical inpatients without prophylaxis, the risk of VT varies substantially according to the disease motivating hospitalization and risk factor exposure. Previous studies found the highest prevalence of VT in bedridden medical inpatients i 3°~~( 4), intensive care unit patients (29fl%) ( 1 6), and patients with heart failure or chest infection (26%) (6) . However, the prevalence of VT in our population was similar to that in medical populations receiving LMWH in controlled studies, estimated to be between 0.2% and 4.8% (8, 17, 18) . In the study reported by Samama et al. (9) , the prevalence of VT under prevention was higher, but this study selected patients with known high-risk factors. To our knowledge, few previous studies l'~ ) have investigated the prevalence of LMWH prophylaxis for VT among medical inpatients and were consistent with our findings estimated to be 30%. In our study, a small proportion of patients was given high doses of LMWH. The small proportion of patients at high risk for VT (6%) could explain this observation if we assume that only patients at high risk should be given high doses. However, consistent with the findings of previous studies (1, 15) , our results suggested that risk factors for VT did not influence the choice of dose in our hospital. The only factor that we found associated with a high dose was a body mass index over 30, i.e., obesity. Moreover, Samama et al. (9) clearly showed that only high-dose prophylactic treatment reduced VT risk in medical patients. Therefore, our results suggested that current LMWH prescription practice should be changed because only a few patients received high doses.
Mentifying risk factors for VT under prevention was one of the objectives of our observational study, along with improving prevention. The most striking result of our study was the higher prevalence of VT among patients receiving prophylaxis than among those patients not given prophylaxis.. Only one study has addressed risk factors for VT for patients given LMWH ( I &dquo;~); only history afi VT was found to be a risk marker. We found that old age and history af VT were independent risk factors for inpatients with '~JT given prophylaxis. Thus, suggest that preventive measures should particularly target inpatients with these risk factors. Furthermore, using drug prophylaxis for a large proportion of inpatients might also lead to other VT-preventive rn~~~ura~' (i.e.,' compression stockings or early mobilization walking) ' being neglected.
Our study has some limitations. We performed a cross-sectional survey on a series of given days to assess the prevalence of VT in current prescription practice. This observational study was not designed to evaluate the efficacy of LMWH, which can only be demonstrated by a'~lini~al trial. For our study to reflect the hospitalized populations and include a sufficient number of inpatients, we estimated from previous studies (8, 18, 19 ) that five given days were necessary. However, the prevalence of VT in current practices of care was lower than expected.
This finding led to a lack of power in the risk factor analysis. Thus, some true risk factors may not have been identified. Because the thrombotic events were diagnosed several days after admission, VT could be considered to be a consequence of the hospital ization. We considered VT on the basis of clinicians' diagnoses, such that only clinical events were included. Diagnosis had to be established by valid laboratory examinations (i.e., echo-doppler, phlebography, lung scan, or pulmonary angiography). For patients with suspected deep vein thrombosis, the diagnostic accuracy of clinical examination has been estimated to be 65%, and the diagnostic accuracy of ultrasonography has been estimated to be 80% (20, 21) . However, the accuracy increases when risk factors are included in the evaluation. Considering only clinical events could lead to an underestimation of the number of VT cases. However, unsuspected VT is usually distal without clinical significance and is associated with only a low risk of further complication (22) . In our study, clinically ' significant VT was probably rarely undiagnosed because on the next given day, the responsible physician was asked if VT had appeared since the previous day of survey. Also, the rate of VT in our study was similar to the of VT in other studies of populations under prophylaxis with LMWH. Our approach was based on the intention of selecting only events requiring treatment.
CONCLUSION
The originality of our study was to analyze VT in medical inpatients at a single institution, treated according to current prophylactic practice. This current practice led to many patients receiving LMWH. Our study showed a prevalence of VT higher among treated than untreated patients. Possibly the dose of LMWH should be adapted according to the risk factors for VT, and other measures of prevention should be considered and developed.
